Significance of antigen and epitope specificity in tuberculosis
- 1Guy’s Hospital Campus of Kings College London, London, UK
- 2Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
Tuberculosis (TB) remains a major global health problem, because (i) diagnosis is usually made too late to avoid spread of infection to contacts; (ii) vaccination with bacillus Calmette–Guérin (BCG) does not prevent the most prevalent pulmonary disease; and (iii) defaulting from lengthy chemotherapy leads to an increase in drug resistant strains. The continued impact of human immunodeficiency virus (HIV) co-infections remains a major aggravating factor in TB resurgence. Intensive research on the specificity and function of immunological responses is of major importance since protective host defense is critically dependent on T cells, which selectively recognize only certain antigens and epitopes of the tubercle bacillus. Such knowledge is therefore necessary for designing a novel effective vaccine and better diagnostic tools. The specificity of the host immune response may also help to explain how the intracellular tubercle bacilli evade host resistance, probably by decoy pro-inflammatory actions of some of their antigens and/or immunomodulatory constituents, which lead to chronic infection and lung pathology.
The 12 articles in this Research Topic in the section Microbial Immunology of the journal Frontiers in Immunology review current knowledge, as well as gaps in our understanding of the mechanisms and functions of T and B cell recognition of antigens and constituent epitopes of Mycobacterium tuberculosis (Mtb). The abundant occurrence of major histocompatibility complex (MHC) class II-permissive epitopes in tubercle bacilli has important implications for the development of both subunit vaccines and diagnostic tests (1, 2). Moreover, an evolutionary interpretation has been that selection of Mtb strains carrying protective MHC-permissive epitopes could have extended the survival of infectious individuals and hence was advantageous for the protracted aerosol transmission of the pathogen (1).
Better understanding of the “antigenome” of Mtb has been advancing with the aid of new powerful strategies for the identification of antigens and its epitope determinants. These methods include bioinformatic approaches toward genome wide predictive algorithms for HLA binding and high-throughput tetramer generation (2). Hypothesis driven approaches or hypothesis free searches of the whole Mtb genome and functional screening algorithms led to the evaluation of candidate antigens, which are recognized well by T cells from latently infected individuals. They involve antigens expressed in vivo, encoded by the DosR regulon, resuscitation promoting factor (Rpf) proteins, and new HLA-class Ia or Ib (HLA-E) restricted Mtb epitopes, recognized by classical and non-classical CD8 T cells (3).
Mycobacterium tuberculosis-specific epitopes of immunodominant and HLA-permissive nature have been used extensively in IFNγ release assays (IGRAs). Several test kits can detect latent Mtb infection with better specificity than the tuberculin based skin test. However, these kits still need improving on their sensitivity and fail to distinguish active TB from latent infection. Moreover, biomarkers for predicting the risk of latent TB progressing into active TB are yet to be found (1, 3, 4). Further research on possible associations between epitope specificity and the phenotype of responding T cells could be an area of potential importance. Polyfunctional T cells have been associated with protective immunity on the grounds that the number of T cells producing IFNγ, IL-2, and/or tumor necrosis factor-α (TNFα) is correlated with vaccine induced protection in models of infectious diseases (4). However, the role of these cells is a subject of debate, since they are readily detectable also in patients with active or past TB. Although these cytokines are produced by several cell types [CD4, CD8, TCRγδ, mucosa-associated invariant T cells (MAIT), CD1-restricted T cells, and natural killer (NK) cells], it is significant that CD4 T cell depletion cannot be compensated with cell types other than CD4 T cells. Epitope-specific serum antibody levels in TB patients have been found to be influenced by the pulmonary bacterial load (associated with HLA-DR15), recent exposure to infection, and response to chemotherapy (5).
Identifying those antigenic determinants, which lead to host protection, is mandatory for designing more effective vaccination strategies. A recently failed vaccine trial in children employed Ag85A, which is highly immunogenic, but changes in its expression in infected cells could influence the susceptibility of infected cells to host immunity (6). Hence, there is a need to select suitable candidate antigens by more rigorous comparison of their protective capacity in animal vaccination models, before proceeding toward evaluation in human trials. In addition to antigen specificity, the success of a subunit vaccine may lie in its presentation, i.e., in the adjuvant formulation. To this effect, the fusion of antigens with interleukins, lipids, lipoproteins, and immune stimulatory peptides has been employed (7). Continued efforts to obtain better protection using recombinant strains of BCG engage over-expression of either Mtb-specific antigens (which had been lost during the attenuation process of BCG) or of some cytokines (IL-2, IL-12, IL-15, and GM-CSF) (8).
Although classical CD4 and CD8 T cells recognize peptide epitopes bound to MHC, molecules with different chemical structures could be of potential importance. Thus, T cells recognizing lipid antigens may contribute to natural host protection and might potentially be exploited for subunit based vaccination (9). Another structural aspect is the role of post-translational modifications of proteins identified using mass spectrometry-based proteomics (10). Recent attention to the proline–glutamic acid (PE) family of cell surface expressed proteins has been due to their immunomodulatory properties and possible evasion from host immunity by antigenic variation. Immunogenicity was attributed to the PE domain, while the specific epitopes were localized within the polymorphic GC-rich sequence (PGRS) domain. However, sensitization in human beings was found to be associated with BCG vaccination, rather than latent Mtb infection (11). Apparently, still other families of antigens need to be evaluated in the search for biomarkers, which could distinguish between stable protection and a tendency for recrudescence in latently infected populations and also for monitoring the efficacy of protection following prophylactic vaccination (12).
In conclusion, further research on Mtb antigen and epitope specificities seems mandatory for realizing the crucially important aims of both prophylactic and post exposure vaccination against TB. Advancing the knowledge of antigenic determinants is essential also for differentiating patients with active TB from latently infected healthy subjects. There is potential in the ambitious search for specific immunological biomarkers for predicting the reactivation of TB in populations, both without and with HIV infection. These endeavors will undoubtedly need to be combined with better knowledge of the functional phenotypes of the respective T cell subsets. Other potential avenues are the construction of fusion proteins with improved vaccine adjuvanticity (7) and the proposed construction of T cell receptor (TCR)-like ligands for immunotherapy (1). Future research may benefit also from advances in computer algorithm based analysis of Mtb epitopes and host cytokine signatures, as well as from reduced costs of DNA and RNA sequencing and synthetic peptide libraries.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
3. Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff THM. Innovative strategies to identify M. tuberculosis antigens and epitopes using genome-wide analyses. Front Immunol (2014) 5:256. doi:10.3389/fimmu.2014.00256
4. Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N. Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. Front Immunol (2014) 5:180. doi:10.3389/fimmu.2014.00180
7. Junqueira-Kipnis AP, Marques Neto LM, Kipnis A. Role of fused Mycobacterium tuberculosis immunogens and adjuvants in modern tuberculosis vaccines. Front Immunol (2014) 5:188. doi:10.3389/fimmu.2014.00188
8. da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP. Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol (2014) 5:152. doi:10.3389/fimmu.2014.00152
10. van Els CACM, Corbière V, Smits K, van Gaans-van den Brink JAM, Poelen MCM, Mascart F, et al. Toward understanding the essence of post-translational modifications for the Mycobacterium tuberculosis immunoproteome. Front Immunol (2014) 5:361. doi:10.3389/fimmu.2014.00361
11. Cohen I, Parada C, Acosta-Gío E, Espitia C. The PGRS domain from PE_PGRS33 of Mycobacterium tuberculosis is target of humoral immune response in mice and humans. Front Immunol (2014) 5:236. doi:10.3389/fimmu.2014.00236
Keywords: tuberculosis, antigens, bacterial, T-lymphocyte, epitopes, MHC restriction, vaccine adjuvant, TB diagnosis
Citation: Ivanyi J and Ottenhoff THM (2014) Significance of antigen and epitope specificity in tuberculosis. Front. Immunol. 5:524. doi: 10.3389/fimmu.2014.00524
Received: 01 September 2014; Accepted: 06 October 2014;
Published online: 23 October 2014.
Edited and reviewed by: Ian Marriott, University of North Carolina at Charlotte, USA
Copyright: © 2014 Ivanyi and Ottenhoff. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: firstname.lastname@example.org; email@example.com